CAS 2138924-36-2

Fórmula: C25H32N2O4S

InChI: InChI=1S/C25H32N2O4S/c1-19(2)15-17-26-25(29)23(14-11-21-7-5-4-6-8-21)27-24(28)16-18-32(30,31)22-12-9-20(3)10-13-22/h4-10,12-13,16,18-19,23H,11,14-15,17H2,1-3H3,(H,26,29)(H,27,28)/b18-16+/t23-/m0/s1

Clave InChI: BLEQGDOEDLJWCG-NGIFANIDSA-N

SMILES: CC1=CC=C(C=C1)S(=O)(=O)/C=C/C(=O)N[C@@H](CCC2=CC=CC=C2)C(=O)NCCC(C)C

WRR139

CAS: 2138924-36-2

WRR139

Fórmula: C₂₅H₃₂N₂O₄S

Pureza: 99%

Peso molecular: 456.6

Ref: 54-OR1130752

WRR139

CAS: 2138924-36-2

Fórmula: C₂₅H₃₂N₂O₄S

Pureza: 99%

Peso molecular: 456.5976

Ref: IN-DA0201DW

WRR139

CAS: 2138924-36-2

WRR139 is an NGLY1 inhibitor that impairs Nrf1 processing and sensitizes cancer cells to proteasome inhibitors.

Fórmula: C₂₅H₃₂N₂O₄S

Pureza: 99.90%

Forma y color: White Solid

Peso molecular: 456.6

Ref: TM-T80771

WRR139

CAS: 2138924-36-2

WRR139 is an analog of a medicinal compound that has shown promising anticancer activity. It works as an inhibitor of certain kinases, which are enzymes involved in cell cycle regulation and protein synthesis. By inhibiting these kinases, WRR139 induces apoptosis (programmed cell death) in cancer cells, leading to tumor shrinkage. This compound has been tested on human urine samples and has shown potent anticancer activity against various types of cancer. WRR139 is a promising candidate for the development of novel kinase inhibitors with potential therapeutic applications in cancer treatment.

Fórmula: C₂₅H₃₂N₂O₄S

Pureza: Min. 95%

Peso molecular: 456.6 g/mol

Ref: 3D-NKD92436